POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.654 EUR | 0.00% |
|
-0.76% | +18.69% |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.27M | Sales 2022 | 674K 718K | Capitalization | 27.16M 28.93M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -24.5M | Net income 2022 | -31M -33.02M | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.2M | Net Debt 2022 | 32.74M 34.87M | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
| 1 day | +2.29% | ||
| 1 week | +2.45% | ||
| Current month | +29.15% | ||
| 1 month | +23.20% | ||
| 3 months | +73.77% | ||
| 6 months | +88.98% | ||
| Current year | +21.42% |
1 week
0.60
0.68
1 month
0.480.90
Current year
0.360.90
1 year
0.300.95
3 years
0.307.75
5 years
0.3013.80
10 years
0.3017.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 09-03-05 | |
Sebastien Bolze
FOU | Founder | - | 09-03-05 |
| Founder | - | 09-03-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 15-03-11 |
Pascale Boissel
BRD | Director/Board Member | 57 | 15-03-04 |
Thomas Kuhn
FOU | Founder | 50 | 09-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.654 | 0.00% | 266 582 |
| 24-04-18 | 0.654 | +6.34% | 547,866 |
| 24-04-17 | 0.615 | -4.50% | 148,568 |
| 24-04-16 | 0.644 | -1.23% | 151,526 |
| 24-04-15 | 0.652 | -0.15% | 223,623 |
Real-time Euronext Paris, April 19, 2024 at 04:18 am EDT
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +21.42% | 27.02M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.92% | 21.66B | |
| -18.35% | 20.77B | |
| -8.49% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- POXEL Stock
